Cite

HARVARD Citation

    Liu, J. et al. (2018). Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nature communications. 9 (1), pp. 1-17. [Online]. 
  
Back to record